Analystreport

Lorus Therapeutics, Inc. (NASDAQ: APTO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.50 price target on the stock.

Aptose Biosciences, Inc. - Common Shares  (APTO) 
Last aptose biosciences, inc. - common shares earnings: 3/10 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: aptose.com/investors